Rabies is almost always fatal if untreated
but is 100% vaccine preventable1,2

shield

CDC/ACIP recommended
for rabies PrEP or PEP3

shield

Proven protection
and prevention4

shield

Supply reliability5

Risk Awareness

Rabies risk is unpredictable and underrecognized6,7

RabAvert works to prevent rabies before contact (PrEP) or immediately after contact (PEP)4

Globally, rabies is responsible for 70,000 deaths each year7

statistic statistic

Every year over 100,000 people come in contact with potentially rabid animals in the US, resulting in the need to administer rabies post-exposure prophylaxis to those patients.8

Who is at risk?

People at higher risk for rabies include those who are:

  • who risk

    Traveling to certain international destinations9

  • who risk

    Working with or around animals9

  • who risk

    Exploring the outdoors9

How it spreads

Rabies is transmitted to humans from infected animals, usually through a bite or scratch. Common carriers of rabies1,9:

dog

Dog

99% of global cases7

skunk

Skunk

raccoon

Raccoon

fox

Fox

cat

Cat

bat

Bat

Path of the virus

The lyssavirus travels from the wound site via the peripheral nervous system to attack the central nervous system, leading to progressive brain and spinal cord damage1

Anatomical illustration of the human nervous system showing the brain, spinal cord, and peripheral nerves with a specific nerve pathway highlighted in red.
dog

Virtually 100% fatal

Following the onset of clinical symptoms, the infection is nearly always fatal1

Where it lurks10

Rabies can be found on every continent with the exception of Antarctica1

Map

High risk

Pre-exposure prophylaxis (PrEP) recommended for travelers and people with occupational risks likely to have contact with rabid domestic animals, particularly dogs, bats, and wild carnivores.

Moderate risk

PrEP recommended for travelers to remote areas and people likely to have contact with bats and other wildlife.

Low risk

PrEP recommended for people likely to have regular direct contact with bats and wild carnivores.

No risk

No data

Not applicable

Pre-Exposure

Post-Exposure

RabAvert helps protect those at risk before the unexpected happens

RabAvert works before contact (PrEP) or immediately after contact (PEP).4

RabAvert is especially suited for4:

Traveler with rolling luggage icon passenger

Travelers

Icon of a laboratory worker using a microscope for research

Lab workers

Animal and health care provider resources shield icon

Animal handlers

Military personnel icon showing a Senior Airman E-4 rank style design from the United States Air Force (U.S.A.F.)

Military personnel11

Rabies PrEP provides an added layer of protection and may simplify treatment in case of contact with the rabies virus.12

The RabAvert 3-dose PrEP series was designed intentionally to help
protect your patients, aligned with proven clinical outcomes.4

RabAvert offers efficacy, safety, and tolerability:

100%

titer protection
in trials4

>50 TRIALS

globally studied and
well tolerated4,13,*

~100%

of patients achieved
protection against
rabies virus4

2 YEARS

of persistent
immunity4

*The most common adverse reactions reported after RabAvert administration include injection site reactions, flu-like symptoms, arthralgia, dizziness, lymphadenopathy, nausea, and rash.4

Proven effective to help provide robust protection4

Clinical results

Primary immunization
Studies 1–2 (US)† 100% of subjects had antibody titers >0.5 IU/mL by Day 28
Studies 3–4
(Croatia, Thailand)‡		 100% of subjects had antibody titers >0.5 IU/mL by Day 14
Booster doses
Study 1 (Thailand)§ Titers increased from 1.91 IU/mL before booster to 23.66 IU/mL on Day 30 after one booster dose
Study 2|| Booster response was observed in 100% of subjects Day 14
Study 3 (US) 100% of subjects had significant increase in titers after booster
The minimum accepted antibody titer is a 1:5 conversion as specified by the CDC and ≥0.5 IU/mL as specified by WHO.

Clinical studies of RabAvert have shown it to be generally well tolerated

Anaphylaxis, meningitis, neuroparalytic events such as encephalitis, transient paralysis, Guillain-Barré syndrome, myelitis, retrobulbar neuritis, and multiple sclerosis have been reported to be temporally associated with the use of RabAvert. A patient’s risk of acquiring rabies must be carefully considered before discontinuing vaccination.4

In clinical trials with RabAvert, the most common adverse reactions were injection site reactions (erythema, induration, and pain); flu-like symptoms (asthenia, fatigue, fever, headache, myalgia, and malaise); arthralgia; dizziness; lymphadenopathy; nausea; and rash.4

†Two studies (n=101).

‡Croatia study (n=25); Thailand study (n=22).

§Preexposure boosters were administered to 10 individuals, all of which demonstrated antibody titers of >0.5 IU/mL at baseline (Day 0).

||IM booster dose of RabAvert was administered to all subjects (35/35), regardless of primary vaccine (RabAvert or HDCV).

Individuals (n=22) known to have been immunized with HDCV.

GMT=geometric mean titers; HDCV=human diploid cell vaccine; HRIG=human rabies immune globulin; IM=intramuscular; IU=international unit; WHO=World Health Organization.

Pre-exposure prophylaxis (PrEP) dosing

Pre-exposure prophylaxis (PrEP) dosing

  • Only requires 1 dose per visit4
  • PrEP dosing schedule is Day 0, Day 7, Day 21/284
  • PrEP eliminates the need for HRIG & reduces Vx doses post-exposure12

PrEP dosing schedule4

According to the FDA-approved prescribing information, RabAvert® is administered
intramuscularly in 3 doses on Day 0, Day 7, and Day 21 or 28

Rabies vaccine pre-exposure prophylaxis (PrEP) 3-dose schedule diagram showing 1.0 mL injections on Day 0, Day 7, and Day 21 or 28

*Please note that current CDC/ACIP dosing recommendations (2022) differ from those in the prescribing
information, no longer calling for a third dose in the primary series.3

A BOOSTER DOSE may be advisable depending on the results of serological testing for the antibody titer level.4

  • For those with continuous rabies exposure, as often as every 6 months
  • For those with frequent rabies exposure, as often as every 2 years

Pre-exposure vaccination does not eliminate the need for additional treatment after a known rabies exposure.

RabAvert is administered as a common intramuscular injection4

The trusted, reliable choice for urgent care

RabAvert works before contact (PrEP) or immediately after contact (PEP).4

Dependably at hand when
you need it

Rabies symptoms can proceed quickly from nonspecific flu-like symptoms to inflammation of the brain and spinal cord, eventually causing paralysis, coma, and death. You need a treatment that is ready to go when you need it and works for your office staff4:

Preferred in Integrated
Delivery Networks (IDNs)5

RabAvert offers efficacy, safety, and tolerability:

100%

titer protection
in trials4

>50 TRIALS

globally studied and
well tolerated4,13,*

~100%

of patients achieved
protection against
rabies virus4

*The most common adverse reactions reported after RabAvert administration include injection site reactions, flu-like symptoms, arthralgia, dizziness, lymphadenopathy, nausea, and rash.4

Proven effective to help provide robust protection4

Clinical results

When administered according to the recommended postexposure regimens, subjects attained protective titers4,†
In studies conducted outside of the US, 158/160 patients by Day 14 and 215/216 patients by Days 28–38 produced antibody levels >0.5 IU/mL
Among the 203 patients in post-exposure trials who were followed for at least 10 months, 0 cases of rabies were observed4
The minimum accepted antibody titer is a 1:5 conversion as specified by the CDC and ≥0.5 IU/mL as specified by WHO

Clinical studies of RabAvert have shown it to be generally well tolerated

Anaphylaxis, meningitis, neuroparalytic events such as encephalitis, transient paralysis, Guillain-Barré syndrome, myelitis, retrobulbar neuritis, and multiple sclerosis have been reported to be temporally associated with the use of RabAvert. A patient’s risk of acquiring rabies must be carefully considered before discontinuing vaccination.4

In clinical trials with RabAvert, the most common adverse reactions were injection site reactions (erythema, induration, and pain); flu-like symptoms (asthenia, fatigue, fever, headache, myalgia, and malaise); arthralgia; dizziness; lymphadenopathy; nausea; and rash.4

†WHO regimen of 5 to 6 IM injections of 1 mL (Days 0, 3, 7, 14, 30, and one optionally on Day 90). RabAvert should be administered as 5 injections of 1 mL each at Days 0, 3, 7, 14, and 28 in conjunction with HRIG on Day 0.

HRIG=human rabies immune globulin; IM=intramuscular; IU=international unit; WHO=World Health Organization.

Post-exposure prophylaxis (PEP) dosing<sup>4</sup>

Post-exposure prophylaxis (PEP) dosing4

  • The essential components of rabies post-exposure prophylaxis are prompt local treatment of wounds and administration of both human rabies immune globulin (HRIG) and vaccine
  • Post-exposure prophylaxis should begin the same day exposure occurred or as soon after exposure as possible
  • Ensure patients understand the need to promptly initiate and complete the full course of doses

PEP dosing schedule4

2 doses if patient has completed PrEP; 5 doses if not previously vaccinated
(Day 0, Day 3, Day 7, Day 14, Day 28)

Previously unvaccinated

Rabies post exposure prophylaxis (PEP) 5 dose vaccination schedule Day 0, 3, 7, 14, and 28

Previously vaccinated

A medical dosing schedule diagram showing two 1.0 ML injections. The first injection is labeled 'Day 0' and the second injection is labeled 'day 3'

According to the FDA-approved prescribing information, the HRIG injection is followed by a series of 5 individual injections of RabAvert® (1.0 mL each) given intramuscularly at a site anatomically distant from the HRIG injection on Days 0, 3, 7, 14, and 28.4

Please note the CDC/ACIP recommendations differ, calling for a 5th dose on Day 28 only for patients who are immunocompromised.14

HRIG should not be administered to previously vaccinated patients. Two individual injections of
RabAvert® (1.0 mL each) should be given intramuscularly on Day 0 and Day 3.4

RabAvert is administered as a common intramuscular injection4

Contact your RabAvert rep to discuss availability

Order RabAvert now for urgent PEP readiness.

Ask your patients about their work and travel plans, and encourage them to make
travel health appointments to ensure they are protected worldwide.

Request a RabAvert Representative:

    Please select

    *Required.

    Sign up for updates and other RabAvert communications.

    By clicking "Sign up," you agree to disclose your personal information to Bavarian Nordic and to be contacted by Bavarian Nordic and their agents in the future regarding products, services, and/or information related to RabAvert®. For more information about Bavarian Nordic's privacy practices, please visit https://rabavert.com/privacy-policy/.

    Thank you! A RabAvert representative will be in touch shortly.

    References:

    1. WHO. Rabies key facts. Updated June 5, 2024. Accessed August 28, 2025. https://www.who.int/news-room/fact-sheets/detail/rabies
    2. WHO. Vaccinating against rabies to save lives. Accessed January 2024. https://www.who.int/activities/vaccinating-against-rabies-to-save-lives
    3. Rao AK, Briggs D, Moore SM, et al. Use of a modified preexposure prophylaxis vaccination schedule to prevent human rabies: recommendations of the Advisory Committee on Immunization Practices — United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(18):619-627.
    4. RabAvert. Prescribing Information. Bavarian-Nordic; 2025.
    5. Data on File. Bavarian Nordic. 2025.
    6. Rupprecht CE, Hanlon CA, Hemachudha T. Rabies re-examined. Lancet Infect Dis. 2002;2(6):327-343.
    7. CDC. Global rabies: what you should know. Updated July 1, 2025. Accessed September 25, 2025. https://www.cdc.gov/rabies/around-world/index.html
    8. CDC. Rabies in the United States: protecting public health. Updated August 4, 2025. Accessed September 25, 2025. https://www.cdc.gov/rabies/php/protecting-public-health/index.html
    9. CDC. About rabies. Updated June 24, 2025. Accessed September 25, 2025. https://www.cdc.gov/rabies/about/index.html
    10. WHO. Distribution of risk levels for humans contacting rabies, worldwide, 2018. Accessed September 25, 2025. https://web.archive.org/web/20201112003913/https://www.who.int/ith/rabies2018.png
    11. U.S. Navy Bureau of Medicine and Surgery. Clinical preventive medicine rabies. Accessed September 25, 2025. https://www.med.navy.mil/Navy-and-Marine-Corps-Force-Health-Protection-Command/Preventive-Medicine/Program-and-Policy-Support/Rabies/
    12. CDC Yellow Book. Rabies. Updated April 23, 2025. Accessed September 25, 2025. https://www.cdc.gov/yellow-book/hcp/travel-associated-infections-diseases/rabies.html
    13. Giesen A, Gniel D, Malerczyk C. 30 years of rabies vaccination with Rabipur: a summary of clinical data and global experience. Expert Rev Vaccines. 2015;14(3):351-367.
    14. CDC. Rabies post-exposure prophylaxis guidance. Updated July 15, 2025. Accessed September 25, 2025. https://www.cdc.gov/rabies/hcp/clinical-care/post-exposure-prophylaxis.html
    INDICATION and IMPORTANT SAFETY INFORMATION

    RabAvert® is indicated for pre-exposure vaccination, in both primary series and booster dose, and for post-exposure prophylaxis against rabies in all age groups.

    To report SUSPECTED ADVERSE REACTIONS, contact Bavarian Nordic at 1-833-365-9596 or the US Department of Health and Human Services by either visiting www.vaers.hhs.gov/reportevent.html or calling 1-800-822-7967.

    Please see full Prescribing Information. 

    This site is intended for US healthcare professionals only.

    I am a US HCP I am a Patient

    You are now leaving RabAvertHCP.com

    Continue Go Back

    We use cookies on this site (and other similar technologies) to enhance your user experience.

    You can manage your Privacy settings on our sites at any time

    Decline Agree

    Thank you for accepting cookies.
    You can now hide this message or select MANAGE PRIVACY to edit your privacy permissions at any time.

    Hide MANAGE PRIVACY

    We use data collected by cookies and JavaScript libraries to improve your browsing experience, analyze site traffic, deliver personalized advertisements, and increase the overall performance of our sites.

    You can manage your permissions for how we may use the data we collect using the settings below. These settings describe the current permissions we have enabled for you as a user of one of our sites. To change any permission, select YES to provide permission or NO to revoke or disallow permissions for any of the Categories or Purposes listed below.

    For more information about how we handle personal information that you provide to us, you may access this site’s Privacy Policy at any time.

    Allow Category Purpose Tools
    Functional

    To monitor the performance of our site and to enhance your browsing experience.

    For example, these tools enable you to communicate with us via live chat.
    Marketing and Analytics

    To understand user behavior in order to provide you with a more relevant browsing experience or personalize the content on our site.

    For example, we collect information about which pages you visit to help us present more relevant information.

    		 Google Analytics
    Advertising

    To personalize and measure the effectiveness of advertising on our site and other websites.

    For example, we may serve you a personalized ad based on the pages you visit on our site.

    		 Facebook Pixel, Google Tag Manager
    N/A Essential

    We use browser cookies that are necessary for the site to work as intended.

    For example, we store your website data collection preferences so we can honor them if you return to our site. You can disable these cookies in your browser settings but if you do the site may not work as intended.
    You can also SUPPRESS or DELETE any information you've shared with us at any time.
    CANCEL SAVE
    INDICATION and IMPORTANT SAFETY INFORMATION

    RabAvert® is indicated for pre-exposure vaccination, in both primary series and booster dose, and for post-exposure prophylaxis against rabies in all age groups.

    • Patients considered to be at risk of a severe hypersensitivity reaction (e.g. anaphylaxis) to RabAvert® or any of its components should receive an alternative rabies vaccine if a suitable product is available.
    • Patients considered to be at risk of a severe hypersensitivity reaction (e.g. anaphylaxis) to RabAvert® or any of its components should receive an alternative rabies vaccine if a suitable product is available. However, in view of the almost invariably fatal outcome of rabies, there is no contraindication to post-exposure prophylaxis, including pregnancy.
    • RabAvert® is contraindicated for pre-exposure vaccination in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to the vaccine or any of its components, which include residues of egg and chicken proteins to which some individuals may be hypersensitive.
    • Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions, as well as medical history for emergence of clinical symptoms of anaphylaxis after exposure to egg or chicken proteins, which RabAvert® contains. Reconstituted RabAvert® also contains processed bovine gelatin and trace amounts of neomycin, chlortetracycline, and amphotericin B, to which some individuals may be hypersensitive. Appropriate medical treatment—including immediately available epinephrine injection (1:1,000), and readily available volume replacement, corticosteroids, and oxygen—must be close at hand to manage possible anaphylactic reactions following administration of RabAvert®. Development of active immunity after vaccination may be impaired in immune-compromised individuals. Radiation therapy, antimalarials, corticosteroids, other immunosuppressive agents, and immunosuppressive illnesses can interfere with the development of active immunity after vaccination and may diminish the protective efficacy of RabAvert®. Pre-exposure vaccination should be administered to such persons with the awareness that the immune response may be inadequate. If persons receiving corticosteroids or other immunosuppressive therapy, or who are immunosuppressed, are vaccinated post-exposure, it is important that a serum sample on Day 14 (the day of the fourth vaccination) be tested for rabies antibody to ensure that an acceptable antibody response has been induced.
    • Pre-exposure vaccination should be postponed in the case of sick and convalescent persons and those considered to be in the incubation stage of an infectious disease. 
    • This product contains albumin, a derivative of human blood. It is present in RabAvert® at concentrations of ≤0.3 mg/dose. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases. A theoretical risk for transmission of Creutzfeld-Jakob disease (CJD) also is considered extremely remote. No cases of transmission of viral diseases or CJD have ever been identified for albumin.
    • Because animal reproductive studies or studies in pregnant or lactating woman have not been conducted with RabAvert®, it is not known whether RabAvert® can cause fetal harm when administered to a pregnant woman, whether it can affect reproduction capacity, or whether it is excreted in animal or human milk with consequent risk to breastfed infants (but many drugs are excreted in human milk). Use RabAvert® in pregnant or lactating women only if clearly needed.
    • Pre-exposure vaccination does not eliminate the need for additional therapy after a known rabies exposure. For intramuscular use only. Unintentional intravascular injection may result in systemic reactions, including shock. 
    • Syncope (fainting) can occur in association with administration of injectable vaccines, including RabAvert®. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope.
    • No data are available regarding the concurrent administration of RabAvert® with other vaccines. 
    • Administration of human rabies immune globulin (HRIG), which along with prompt local cleaning of wounds should take place before post-exposure prophylaxis, must not exceed the recommended dose, since active immunization to the vaccine may be impaired. HRIG should not be administered to previously vaccinated persons as it may blunt their rapid memory response to rabies antigen.

    To report SUSPECTED ADVERSE REACTIONS, contact Bavarian Nordic at 1-833-365-9596 or the US Department of Health and Human Services by either visiting www.vaers.hhs.gov/reportevent.html or calling 1-800-822-7967.

    Please see full Prescribing Information.